Cartherics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
37
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$300K
- Investors
-
2
Cartherics General Information
Description
Developer of gene-edited cell therapy technology designed to treat cancer and endometriosis through targeted immune cell approaches. The company offers an induced pluripotent stem cell-based platform that generates engineered natural killer cells and supports end-to-end discovery and clinical manufacturing, enabling the development of scalable, targeted immune therapies for oncology and women's health treatments across solid tumors and endometriosis indications.
Contact Information
Website
www.cartherics.comCorporate Office
- 12 Ferntree Place
- Notting Hill, Victoria 3168
- Australia
Corporate Office
- 12 Ferntree Place
- Notting Hill, Victoria 3168
- Australia
Cartherics Timeline
Cartherics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | 18-Dec-2024 | $300K | Completed | Generating Revenue | ||
| 3. Later Stage VC (Series B) | 01-Oct-2024 | Completed | Generating Revenue | |||
| 2. Later Stage VC | Completed | Startup | ||||
| 1. Grant | 27-Sep-2022 | $5.4M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cartherics Patents
Cartherics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022220754-A1 | Methods and compositions for generating stem cell-derived immune cells with enhanced function | Pending | 10-Feb-2021 | ||
| CA-3211013-A1 | Methods and compositions for generating stem cell-derived immune cells with enhanced function | Pending | 10-Feb-2021 | ||
| EP-4291660-A1 | Methods and compositions for generating stem cell-derived immune cells with enhanced function | Pending | 10-Feb-2021 | ||
| EP-4291660-A4 | Methods and compositions for generating stem cell-derived immune cells with enhanced function | Pending | 10-Feb-2021 | ||
| JP-2024506067-A | Methods and compositions for generating stem cell-derived immune cells with enhanced function | Pending | 10-Feb-2021 | A61K40/31 |
Cartherics Signals
Cartherics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ScaleReady | Corporation | Minority | ||
| Australian Digital Health Agency | Government |
Cartherics FAQs
-
When was Cartherics founded?
Cartherics was founded in 2016.
-
Where is Cartherics headquartered?
Cartherics is headquartered in Notting Hill, Australia.
-
What is the size of Cartherics?
Cartherics has 37 total employees.
-
What industry is Cartherics in?
Cartherics’s primary industry is Drug Discovery.
-
Is Cartherics a private or public company?
Cartherics is a Private company.
-
What is Cartherics’s current revenue?
The current revenue for Cartherics is .
-
How much funding has Cartherics raised over time?
Cartherics has raised $10.5M.
-
Who are Cartherics’s investors?
ScaleReady and Australian Digital Health Agency have invested in Cartherics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process